[Translation] A randomized, open-label, single-dose, two-period, double-crossover bioequivalence study of tenegliptin hydrobromide tablets in Chinese healthy volunteers: a fasting and fed dose-response study

主要目的：以南京易亨制药有限公司生产的氢溴酸替格列汀片（规格：20 mg）为受试制剂，按生物等效性试验的有关规定，与Mitsubishi Tanabe Pharma Corporation持证的氢溴酸替格列汀片为参比制剂（商品名：泰里安®，规格：20 mg），对比在健康人体内的相对生物利用度，研究两制剂的人体生物等效性。次要目的：观察氢溴酸替格列汀片受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Primary Objective: To investigate the bioequivalence of the test formulation (20 mg) of tenegliptin hydrobromide tablets produced by Nanjing Yiheng Pharmaceutical Co., Ltd.) with the reference formulation (20 mg) of tenegliptin hydrobromide tablets licensed by Mitsubishi Tanabe Pharma Corporation) in healthy volunteers by comparing their relative bioavailability in healthy volunteers. Secondary Objective: To investigate the safety of the test and reference formulations of tenegliptin hydrobromide tablets in healthy volunteers.

Start Date14 Oct 2025

Sponsor / Collaborator

Nanjing Yiheng Pharmaceutical Co., Ltd.

CTR20252533

/ CompletedNot Applicable

氢溴酸替格列汀片在中国健康受试者中单中心、随机、开放、单剂量、两制剂、两周期、两序列、双交叉空腹/餐后状态下生物等效性试验

[Translation] A single-center, randomized, open-label, single-dose, two-formulation, two-period, two-sequence, double-crossover bioequivalence study of tenegliptin hydrobromide tablets in Chinese healthy subjects under fasting/fed conditions

主要研究目的：健康受试者空腹或餐后状态下，单次口服江西施美药业股份有限公司生产的受试制剂氢溴酸替格列汀片（规格：40 mg）或田辺三菱製薬株式会社生产的参比制剂氢溴酸替格列汀片（商品名：Tenelia；规格：40 mg），分别考察空腹或餐后状态下受试制剂与参比制剂在健康受试者体内的药代动力学参数，评价两制剂的生物等效性。次要研究目的：考察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Main study purpose: Healthy subjects were given a single oral dose of the test preparation Tenegliptin Hydrobromide Tablets (Specification: 40 mg) produced by Jiangxi Shimei Pharmaceutical Co., Ltd. or the reference preparation Tenegliptin Hydrobromide Tablets (Trade Name: Tenelia; Specification: 40 mg) produced by Tanabe Mitsubishi Pharmaceutical Co., Ltd. in the fasting or postprandial state, to investigate the pharmacokinetic parameters of the test preparation and the reference preparation in healthy subjects, respectively, and to evaluate the bioequivalence of the two preparations. Secondary study purpose: To investigate the safety of the test preparation and the reference preparation in healthy subjects.

Start Date15 Aug 2025

Sponsor / Collaborator

Jiangxi Shimei Pharmaceutical Co., Ltd.

100 Clinical Results associated with Teneligliptin Hydrobromide Hydrate

100 Translational Medicine associated with Teneligliptin Hydrobromide Hydrate

100 Patents (Medical) associated with Teneligliptin Hydrobromide Hydrate

346

Literatures (Medical) associated with Teneligliptin Hydrobromide Hydrate

14 Oct 2025·CURRENT DIABETES REVIEWS

From Diabetes to Dermatology: The Role of Teneligliptin in Bullous Pemphigoid Development

Article

Author: Khan, Yumna ; Hussain, Md Sadique ; Gupta, Gaurav ; Bisht, Ajay Singh ; Bahl, Gurusha

Abstract::

Bullous pemphigoid (BP) is an autoimmune blistering disease that especially presents in elderly patients, but recently, its incidence has increased in patients treated with inhibitors of dipeptidyl peptidase-4 (DPP-4), among which teneligliptin is widely prescribed as an antidiabetic drug for the treatment of type 2 diabetes mellitus (T2DM). Recent studies describe the association of teneligliptin with the onset of BP, hypothesizing that DPP-4 inhibition could induce immune dysregulation able to trigger autoimmune responses against skin antigens BP180 and BP230. This mini-review discusses the immunomodulatory effects of teneligliptin, immune responses, and chronic inflammation associated with diabetes that predispose patients to BP. It also discusses the clinical implications, such as monitoring for BP in T2DM patients on teneligliptin therapy. Elucidation of this relationship may help in optimizing management strategies by highlighting discontinuation or alternative therapies in the case of a high risk of development of BP.

01 Sep 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Teneligliptin, a DPP4 inhibitor protects dopaminergic neurons in PD models via inhibiting of oxidative stress and ferroptosis

Article

Author: Gu, Liqin ; Pi, Jiakai ; Wang, Wenya ; Huang, Linting ; Liao, Zirou

Parkinson's disease is a progressive neurodegenerative disorder with pathological hallmarks of loss of nigrostriatal dopaminergic neurons. Oxidative stress is one of the pivotal molecular pathways involved. Ferroptosis, a novel form of cell death, is closely associated with oxidative stress and presents a new potential therapeutic target for PD. Amounting reports showed that dipeptidyl peptidase-4 (DPP4) inhibitors, may hold potential for PD treatment. In this study, we found that Teneligliptin, a DPP4 inhibitor, when pretreated in SH-SY5Y cells, alleviated MPP⁺-induced cellular damage, including enhancing cell viability and modulating the Bax/Bcl-2 ratio. Furthermore, Teneligliptin not only inhibited the accumulation of reactive oxygen species (ROS), prevented the decline of mitochondrial membrane potential, decreased malondialdehyde (MDA) levels, restored glutathione (GSH) and superoxide dismutase (SOD) contents, but also lowered ferrous ion levels. At the same time, Teneligliptin restored antioxidant defenses by inhibiting DPP4 to enhance p62-mediated Keap1 degradation, thereby activating the Nrf2 signaling pathway. This upregulated downstream target including HO-1 and xCT, maintaining glutathione peroxidase 4 (GPX4) expression. Finally, Teneligliptin improved behavioral performance and protected dopaminergic neurons in MPTP-induced PD mouse. Taken together, our findings of Teneligliptin as a promising candidate for the treatment of PD warrant further study.

01 May 2025·ANALYTICAL BIOCHEMISTRY

In-vivo microwave-aided spectrofluorimetric characterization of teneligliptin-loaded solid dispersion adsorbate using quality by design approach

Article

Author: Prajapati, Pintu ; Shah, Shailesh ; Shah, Pranav ; Kalam, Mohd Abul ; Kansara, Yashwini ; Ardeshana, Princy ; Pulusu, Veera Shakar ; Haque, Anzarul

This study developed a microwave-aided spectrofluorimetric method for in-vivo characterizing teneligliptin-loaded solid dispersion adsorbate (TNG-SDA) using a quality by design approach. The microwave-aided chemical reaction was applied for derivatization of non-fluorescent teneligliptin with NBD-Cl (7-chloro-4-nitrobenzoxadiazole). TNG-SDA was prepared to enhance the solubility and bioavailability of teneligliptin, a BCS (Biopharmaceutical Classification System) class II drug. The method utilized environmentally friendly solvents and employed analytical quality by design principles for optimization. Critical method parameters were identified through failure mode impact analysis and optimized using response surface modelling. The fluorescence spectra of teneligliptin exhibited linearity across the concentration range of 50-250 ng/mL, with a correlation coefficient of 0.9978. The developed method was found to be accurate, precise, robust, specific and sensitive for estimation of teneligliptin. The method was applied to evaluate in vitro dissolution, pharmacokinetics, and pharmacodynamic of TNG-SDA compared to commercial formulations. Results showed significant improvements in teneligliptin solubility and bioavailability with the developed SDA. The microwave-aided derivatized fluorescent product was characterized by mass spectrometry. The method demonstrated environmental sustainability, robustness, sensitivity, cost-effectiveness, and user-friendliness when evaluated using white analytical chemistry approaches. It provided a sensitive and green alternative to existing hyphenated techniques for nanogram-level teneligliptin detection in pharmacokinetic studies.

News (Medical) associated with Teneligliptin Hydrobromide Hydrate

20 Oct 2022

·www.pharmaindustrial-india.com

Glenmark launches Teneligliptin + Dapagliflozin Fixed-Dose Combination for adults with Type 2 diabetes

Glenmark Pharmaceuticals became the first to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed-dose combination (FDC) for the treatment of adult patients with type 2 diabetes, especially the ones with comorbidities. Marketed under the brand name Zita D; it contains Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg), and must be taken once daily under prescription to improve glycemic control & prevent complications in adult patients with type 2 diabetes, especially the ones with comorbidities. Alok Malik, EVP & Business Head, India Formulations, Glenmark Pharmaceuticals, said, “Diabetes is growing in India at an alarming rate, and eight out of every ten diabetic patients suffer from comorbidities. Glenmark being a leader in the diabetes segment in India is proud to bring Zita D, a well researched and affordable fixed-dose combination, which will significantly improve glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities.

Drug Approval

07 Sep 2017

·www.daiichisankyo.com

Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Launch of CANALIA® Combination Tablets, a type 2 diabetes mellitus treatment agent

PDF (48KB)PDF For Immediate Release Mitsubishi Tanabe Pharma Corporation Daiichi Sankyo Co., Ltd. -Combination of selective DPP-4 inhibitor TENELIA® Tablets and SGLT2 inhibitor CANAGLU® Tablets- Osaka and Tokyo, Japan (September 7, 2017) - Mitsubishi Tanabe Pharma Corporation (hereafter Mitsubishi Tanabe Pharma; Head Office: Chuo-ku, Osaka; President & Representative Director, CEO: Masayuki Mitsuka) and Daiichi Sankyo Co., Ltd. (hereafter Daiichi Sankyo; Head Office: Chuo-ku, Tokyo; Representative Director, President & COO: Sunao Manabe) announced today that both companies would launch CANALIA® Combination Tablets, a type 2 diabetes mellitus treatment agent that combines selective DPP-4 inhibitor TENELIA® Tablets (generic name: teneligliptin) and SGLT2 inhibitor CANAGLU® Tablets (generic name: canagliflozin), in Japan on September 7, 2017, following today’s inclusion of CANALIA® in the National Health Insurance drug price list. Approved for the first time in Japan, CANALIA® Combination Tablets is a combination drug that contains two ingredients, a DPP-4 inhibitor and a SGLT2 inhibitor.Both TENELIA® Tablets and CANAGLU® Tablets are type 2 diabetes mellitus treatment agents originally discovered by Mitsubishi Tanabe Pharma in Japan. CANALIA® Combination Tablets, a combination drug incorporating the above two constituents, is an orally-administered (once daily) agent that lowers blood-glucose levels based on two different mechanisms of action: inhibiting DPP-4 and thereby increasing insulin release according to blood glucose levels; and inhibiting SGLT2 and thereby promoting excretion of glucose into urine. Results of clinical trials conducted in Japanese Type 2 diabetes mellitus patients who have inadequate glycemic control to monotherapy with TENELIA® Tablets or CANAGLU® Tablets demonstrated efficacy, safety and good tolerability. Use of CANALIA® Combination Tablets by patients with type 2 diabetes mellitus whose blood glucose levels are stably controlled by concomitant treatment with TENELIA® Tablets and CANAGLU® Tablets will reduce the number of medicine and improve medication adherence. Use of CANALIA® Combination Tablets by type 2 diabetes mellitus patients who have inadequate glycemic control to monotherapy with TENELIA® Tablets or CANAGLU® Tablets is also expected to result in improved blood glucose control. Currently, marketing of TENELIA® Tabletsis conducted by Daiichi Sankyo, whereas marketing of CANAGLU® Tablets is carried out by Mitsubishi Tanabe Pharma. Marketing of CANALIA® Combination Tablets will be conducted by Daiichi Sankyo, and both companies will co-promote the product, as is the case with TENELIA® Tablets and CANAGLU® Tablets. Mitsubishi Tanabe Pharma and Daiichi Sankyo aim to contribute to the treatment of patients with diabetes by maximizing the product values of the above three agents in the diabetes treatment drug markets as well as by engaging in prompt and appropriate promotion activities through the alliance between both companies. For further information, please contact: Mitsubishi Tanabe Pharma Corporation Corporate Communications Department TEL: +81-6-6205-5211 Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126

Drug Approval

03 Jul 2017

·www.daiichisankyo.com

Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Application approved in Japan for CANALIA® Combination Tablets, a type 2 diabetes mellitus treatment agent

PDF (41KB)PDF For Immediate Release Mitsubishi Tanabe Pharma Corporation Daiichi Sankyo Co., Ltd. -Combination of selective DPP-4 inhibitor TENELIA® Tablets and SGLT2 inhibitor CANAGLU® Tablets- Osaka and Tokyo, Japan (July 3, 2017) - Mitsubishi Tanabe Pharma Corporation (hereafter Mitsubishi Tanabe Pharma; Head Office: Chuo-ku, Osaka; President & Representative Director, CEO: Masayuki Mitsuka) and Daiichi Sankyo Co., Ltd. (hereafter Daiichi Sankyo; Head Office: Chuo-ku, Tokyo; Representative Director, President & COO: Sunao Manabe) announced today that on July 3, 2017, Mitsubishi Tanabe Pharma received manufacturing and sales approval for CANALIA® Combination Tablets, a type 2 diabetes mellitus treatment agent that combines selective DPP-4 inhibitor TENELIA® Tablets (generic name: teneligliptin) and SGLT2 inhibitor CANAGLU® Tablets (generic name: canagliflozin), from the Japanese Ministry of Health, Labour and Welfare. The approval is for an indication of type 2 diabetes mellitus. Approved for the first time in Japan, CANALIA® Combination Tablets is a combination drug that contains two ingredients, a DPP-4 inhibitor and a SGLT2 inhibitor.Both TENELIA® Tablets and CANAGLU® Tablets are type 2 diabetes mellitus treatment agents originally discovered by Mitsubishi Tanabe Pharma in Japan. CANALIA® Combination Tablets, a combination drug incorporating the above two constituents, is an orally-administered (once daily) agent that lowers blood-glucose levels based on two different mechanisms of action: inhibiting DPP-4 and thereby increasing insulin release according to blood glucose levels; and inhibiting SGLT2 and thereby promoting excretion of glucose into urine. Results of clinical trials conducted in Japanese T2DM patients who have inadequate glycemic control to TENELIA® Tablets or CANAGLU® Tablets demonstrated efficacy, safety and good tolerability. Use of CANALIA® Combination Tablets by patients with type 2 diabetes mellitus whose blood glucose levels are stably controlled by concomitant treatment with TENELIA® Tablets and CANAGLU® Tablets will enhance convenience and improve medication adherence. Use of CANALIA® Combination Tablets by type 2 diabetes mellitus patients who have inadequate glycemic control to monotherapy with TENELIA® Tablets or CANAGLU® Tablets is also expected to result in improved blood glucose control. Currently, marketing of TENELIA® Tabletsis conducted by Daiichi Sankyo, whereas marketing of CANAGLU® Tablets is carried out by Mitsubishi Tanabe Pharma. Marketing of CANALIA® Combination Tablets will be conducted by Daiichi Sankyo, and both companies will co-promote the product, as is the case with TENELIA® Tablets and CANAGLU® Tablets. Mitsubishi Tanabe Pharma and Daiichi Sankyo aim to contribute to the treatment of patients with diabetes by maximizing the product values of the above three agents in the diabetes treatment drug markets as well as by engaging in prompt and appropriate promotion activities through the alliance between both companies. For further information, please contact: Mitsubishi Tanabe Pharma Corporation Corporate Communications Department TEL: +81-6-6205-5211 Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126

Drug Approval

100 Deals associated with Teneligliptin Hydrobromide Hydrate

External Link

KEGG	Wiki	ATC	Drug Bank
D09756	Teneligliptin Hydrobromide Hydrate	A10B	DB11950

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Japan	Mitsubishi Tanabe Pharma Corp.	29 Jun 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus	Phase 1	-	Handok, Inc.	01 Jan 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


TOP RENAL (ADA2023)	Not Applicable	Type 2 diabetes mellitus with established diabetic nephropathy	377	Teneligliptin	cxbrcgougk(qamgwmfzix) = wlyhnnuwuo tcubkmggcr (socculmzhr )	Positive	20 Jun 2023
NCT02916706 (CTgov)	Phase 3	Diabetes Mellitus, Type 2	254	Teneligliptin 20mg (Teneligliptin 20mg)	ckrnyctnzh(mqcbrhfzxy) = nbrfjkdbov czskpydtlj (yhczcfevyr, 0.06) View more	-	28 Jan 2022
				Placebo (Placebo)	ckrnyctnzh(mqcbrhfzxy) = qadvkvmfzy czskpydtlj (yhczcfevyr, 0.06) View more
NCT02924064 (CTgov)	Phase 3	Diabetes Mellitus, Type 2	247	Teneligliptin+Metformin (Teneligliptin 20mg + Metformin)	hdxszzpcbh(kgbvlktujk) = mvoiztpcnr jckollxjvf (phqbaegcei, 0.07) View more	-	28 Jan 2022
				Placebo+Metformin (Placebo + Metformin)	hdxszzpcbh(kgbvlktujk) = jyqaeutxre jckollxjvf (phqbaegcei, 0.07) View more
NCT03508323 (EASD2020)	Phase 4	Diabetes Mellitus, Type 2	65	Teneligliptin 20 mg	gsjggzcuhd(ywkxzljeyj) = hiqwuuwych mwioduqqht (nukbusezbs ) View more	Positive	24 Sep 2020
NCT02354222 (CTgov)	Phase 3	Diabetes Mellitus, Type 2	154	Teneligliptin+Canagliflozin (Teneligliptin+Canagliflozin)	feeaqvtjxl(rjcqvfxzrp) = lltqnrpfxe jdzmxcmmqg (lkhbvibyzk, 0.08) View more	-	16 Aug 2018
				Placebo+Canagliflozin (Placebo+Canagliflozin)	feeaqvtjxl(rjcqvfxzrp) = ppeypjoxhf jdzmxcmmqg (lkhbvibyzk, 0.08) View more
NCT02354222 (Pubmed \| Diabetes Obes Metab) Manual	Phase 3	Diabetes Mellitus, Type 2	-	Canagliflozin+teneligliptin	ufsnlrzzwd(pwqiyraohk): difference = -0.94, P-Value = <0.001	Positive	01 Feb 2018
				Canagliflozin+Placebo
NCT02081599 (Pubmed \| Expert Opin Pharmacother) Manual	Phase 4	Diabetes Mellitus, Type 2	148	teneligliptin	oooivkczie(mvhixduaoj) = kryaabknwx ebbutwwgiu (yapmkraalw, 0.11) View more	Positive	01 Sep 2017
				Placebo	uwplxtakgr(ziiwunlnjj) = rbvyhxbaax vkdwafisan (rzjybthbgi )
NCT02354235 (Pubmed \| Diabetes Obes Metab) Manual	Phase 3	Diabetes Mellitus, Type 2	138	canagliflozin as add-on therapy to teneligliptin	koazewmmws(crlhykqluj): difference = -0.88, P-Value = < 0.001	Positive	01 Jun 2017
				Placebo+teneligliptin
NCT02081599 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	148	Insulin+Teneligliptin (Placebo/Teneli (Teneligliptin) + Insulin)	nrkvsdlbtw(liabdydsuc) = nvcemzloog cupqeleuzy (jmpoznbsdm, 0.08) View more	-	05 Jan 2017
				Insulin+Teneligliptin (Teneli (Teneligliptin) /Teneli + Insulin)	nrkvsdlbtw(liabdydsuc) = oxemoijsug cupqeleuzy (jmpoznbsdm, 0.08) View more
CTRI/2014/01/004315 (EASD2016)	Phase 3	Diabetes Mellitus, Type 2	237	Teneligliptin 20 mg	bjtxqbkgnc(hormtgynlv): difference = 0.555 (95% CI, 0.176 - 0.934), P-Value = 0.0043 View more	Positive	13 Sep 2016
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis